Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity.

Fonfria E, Elliott M, Beard M, Chaddock JA, Krupp J.

Toxins (Basel). 2018 Jul 4;10(7). pii: E278. doi: 10.3390/toxins10070278. Review.

2.

Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors.

Masuyer G, Davies JR, Moore K, Chaddock JA, Ravi Acharya K.

Sci Rep. 2015 Sep 1;5:13397. doi: 10.1038/srep13397.

3.

Engineered botulinum neurotoxins as new therapeutics.

Masuyer G, Chaddock JA, Foster KA, Acharya KR.

Annu Rev Pharmacol Toxicol. 2014;54:27-51. doi: 10.1146/annurev-pharmtox-011613-135935. Epub 2013 Aug 30. Review.

PMID:
24016211
4.

Transforming the domain structure of botulinum neurotoxins into novel therapeutics.

Chaddock J.

Curr Top Microbiol Immunol. 2013;364:287-306. doi: 10.1007/978-3-642-33570-9_13. Review.

PMID:
23239358
5.

Engineering botulinum neurotoxin domains for activation by toxin light chain.

Stancombe PR, Masuyer G, Birch-Machin I, Beard M, Foster KA, Chaddock JA, Acharya KR.

FEBS J. 2012 Feb;279(3):515-23. doi: 10.1111/j.1742-4658.2011.08444.x. Epub 2011 Dec 23.

6.

Structures of engineered Clostridium botulinum neurotoxin derivatives.

Masuyer G, Stancombe P, Chaddock JA, Acharya KR.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Dec 1;67(Pt 12):1466-72. doi: 10.1107/S1744309111034671. Epub 2011 Nov 25.

7.

Targeted secretion inhibitors-innovative protein therapeutics.

Keith F, John C.

Toxins (Basel). 2010 Dec;2(12):2795-815. doi: 10.3390/toxins2122795. Epub 2010 Dec 3. Review.

8.

Engineering toxins for 21st century therapies.

Chaddock JA, Acharya KR.

FEBS J. 2011 Apr;278(6):899-904. doi: 10.1111/j.1742-4658.2011.08013.x. Epub 2011 Feb 3.

9.

Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B.

Masuyer G, Beard M, Cadd VA, Chaddock JA, Acharya KR.

J Struct Biol. 2011 Apr;174(1):52-7. doi: 10.1016/j.jsb.2010.11.010. Epub 2010 Nov 13.

PMID:
21078393
10.

Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A.

Masuyer G, Thiyagarajan N, James PL, Marks PM, Chaddock JA, Acharya KR.

Biochem Biophys Res Commun. 2009 Mar 27;381(1):50-3. doi: 10.1016/j.bbrc.2009.02.003. Epub 2009 Feb 8.

PMID:
19351593
11.

Botulinum neurotoxin A and neurotoxin E cleavage products of synaptosome-associated protein of 25 kd exhibit distinct actions on pancreatic islet beta-cell Kv2.1 channel gating.

He Y, Elias CL, Huang YC, Gao X, Leung YM, Kang Y, Xie H, Chaddock JA, Tsushima RG, Gaisano HY.

Pancreas. 2008 Jan;36(1):10-7. doi: 10.1097/mpa.0b013e31812eee28.

PMID:
18192874
12.

Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B, and C and their applications.

Sutton JM, Wayne J, Scott-Tucker A, O'Brien SM, Marks PM, Alexander FC, Shone CC, Chaddock JA.

Protein Expr Purif. 2005 Mar;40(1):31-41.

PMID:
15721769
13.

Crystal structures of Erythrina cristagalli lectin with bound N-linked oligosaccharide and lactose.

Turton K, Natesh R, Thiyagarajan N, Chaddock JA, Acharya KR.

Glycobiology. 2004 Oct;14(10):923-9. Epub 2004 Jun 16.

PMID:
15201215
14.

Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies.

Hall YH, Chaddock JA, Moulsdale HJ, Kirby ER, Alexander FC, Marks JD, Foster KA.

J Immunol Methods. 2004 May;288(1-2):55-60.

PMID:
15183085
15.

Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain.

Chaddock JA, Purkiss JR, Alexander FC, Doward S, Fooks SJ, Friis LM, Hall YH, Kirby ER, Leeds N, Moulsdale HJ, Dickenson A, Green GM, Rahman W, Suzuki R, Duggan MJ, Quinn CP, Shone CC, Foster KA.

Mov Disord. 2004 Mar;19 Suppl 8:S42-7.

PMID:
15027053
16.

Isolation of the gene and large-scale expression and purification of recombinant Erythrina cristagalli lectin.

Stancombe PR, Alexander FC, Ling R, Matheson MA, Shone CC, Chaddock JA.

Protein Expr Purif. 2003 Aug;30(2):283-92.

PMID:
12880778
17.

Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.

Turton K, Chaddock JA, Acharya KR.

Trends Biochem Sci. 2002 Nov;27(11):552-8. Review.

PMID:
12417130
18.

Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A.

Chaddock JA, Herbert MH, Ling RJ, Alexander FC, Fooks SJ, Revell DF, Quinn CP, Shone CC, Foster KA.

Protein Expr Purif. 2002 Jul;25(2):219-28.

PMID:
12135553
19.

Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin.

Duggan MJ, Quinn CP, Chaddock JA, Purkiss JR, Alexander FC, Doward S, Fooks SJ, Friis LM, Hall YH, Kirby ER, Leeds N, Moulsdale HJ, Dickenson A, Green GM, Rahman W, Suzuki R, Shone CC, Foster KA.

J Biol Chem. 2002 Sep 20;277(38):34846-52. Epub 2002 Jul 8.

Supplemental Content

Loading ...
Support Center